Surgical Excision
Treatment for Non Melanoma Skin Cancer Squamous Cell Carcinoma
Effectiveness
92%
Safety Score
72%
Clinical Trials
7
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
72
DangerousModerateSafe
Treatment Details
Time to Effect
immediate
Treatment Duration
Single procedure
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$400
Side Effect Mgmt:$100
Total Annual:$2,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$25,000/QALY
QALYs Gained
0.9
Outcome-Based Costs
Cost per Responder
$2,717
Cost per Remission
$2,717
Comparison vs Mohs Micrographic Surgery
Cost Difference
$-1,000/year
Less expensive
QALY Difference
-0.15 QALYs
Worse outcomes
Dominance
No dominance
Surgical Excision Outcomes
for Non Melanoma Skin Cancer Squamous Cell Carcinoma
Efficacy Outcomes
Overall Effectiveness
+92%
Response Rate
+92%
Remission Rate
+92%
Common Side Effects
Pain
+30%
Swelling/Bruising
+40%
Infection
+4%
Scarring
+100%
Nerve damage
+3%
Sources:
Active Clinical Trials
6 active trials recruiting for Surgical Excision in Non Melanoma Skin Cancer Squamous Cell Carcinoma
Hair Regrowth Following Partial Thickness Removal of SSCIS
NCT07809191NOT YET RECRUITINGNA
15 participants
INTERVENTIONAL
Started: Sep 1, 2026
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
NCT05108090RECRUITINGNA
94 participants
INTERVENTIONAL
Indianapolis, United States
Started: Oct 25, 2021
Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma
NCT06782399ENROLLING BY INVITATIONEARLY_PHASE1
25 participants
INTERVENTIONAL
Boston, United States
Started: Oct 1, 2025
Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence
NCT07361666NOT YET RECRUITING
400 participants
OBSERVATIONAL
Warsaw, Poland
Started: Dec 23, 2025
Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma
NCT06606028RECRUITING
250 participants
OBSERVATIONAL
San Francisco, United States
Started: Oct 9, 2024
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444RECRUITING
2.29K participants
OBSERVATIONAL
Birmingham, United States +56 more
Started: Sep 7, 2021
Completed Clinical Trials
3 completed trials for Surgical Excision in Non Melanoma Skin Cancer Squamous Cell Carcinoma
EktoTherix™ Regenerative Tissue Scaffold for Repair of Surgical Excision Wounds
NCT02409628COMPLETEDNA
12 participants
INTERVENTIONAL
Middlesbrough, United Kingdom +2 more
Started: Apr 23, 2015
Nanocytology Test to Evaluate Skin Cancer in High Risk Patients
NCT01905891COMPLETEDNA
7 participants
INTERVENTIONAL
Chicago, United States
Started: Jul 1, 2013
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
NCT03633110COMPLETEDPHASE1, PHASE2
24 participants
INTERVENTIONAL
La Jolla, United States +10 more
Started: Aug 29, 2018